Surface Plasmon Resonance Biosensors for Early and Accurate Diagnosis of Neurological Disorders
Year: 2026
Type: preprint
Abstract: Biosensors that use surface plasmon resonance to detect biomarkers in biofluids such as blood and cerebrospinal fluid provide hope for the accurate and early diagnosis of Alzheimer's disease. Aggregated β-amyloid as well as tau proteins are important markers of Alzheimer's disease, and our label-free biosensors can detect trace levels of these molecules. In order to detect changes in the refractive index near the sensor surface, SPR biosensors use light interacting with a thin metal coating, usually gold. Increasing the specificity and sensitivity of SPR sensors to detect several AD biomarkers is the main focus of current research. The SPR signal (usually an angle variation in the SPR curve) is affected when molecules attach to the sensor surface, which affects the refractive index. These alterations allow SPR biosensors to determine the quantity and presence of certain biomarkers. In order to dynamically track the evolution of a disease, SPR biosensors may provide real-time readings of biomarker concentrations. A more complete picture of the illness may be obtained by using SPR technology to detect many indicators concurrently. There are a number of biomarkers linked to Alzheimer's disease that SPR biosensors may detect. These include: Aβ proteins, which may be found in both soluble along with aggregated forms, play a crucial role in the pathophysiology of Alzheimer's disease. Another characteristic of Alzheimer's disease is the abnormal phosphorylated and accumulation of tau protein. Apolipoprotein E (apoE)—ADmin risk is associated with certain apoE mutations. The accuracy of diagnoses made using the CaffeNet Model may be enhanced by the capacity to identify low concentrations of biomarkers with a high degree of sensitivity. Furthermore, classification is accomplished using the Rule Learning technique. For accurate separation from diverse samples and marker identification, this plasmonic sensor only requires nanoparticles of gold and an antibody; no other procedures are required. In normal conditions, we found that the detection limit for amyloid beta (Aβ) 1–40, Aβ 1-42, and τ protein was 34.9 fM, 26 fM, and 23.6 fM, respectively, for each biomarker in the simulated blood, according to the 1, 2.23, and 3.12 nm shifts of the Rayleigh scattering peak on the shape-code plasmon system. Detecting Alzheimer's disease biomarkers has never been easier than with our first-of-its-kind very sensitive shape-code biosensor.
Source: Research Square
Institution: Karpagam Academy of Higher Education
Language: English
Subfield: Atomic and Molecular Physics, and Optics
Field: Physics and Astronomy
Domain: Physical Sciences
Open Access status: green
OpenAlex ID: W7234974120
